The second part of this series examines industrial and medical applications of hemp and emphasize the importance of regular testing for heavy metals to ensure maximum consumer safety.
People may not have to microdose psychedelics to feel their wellbeing benefits – they just have to believe they’ve microdosed them, according to researchers from Imperial College London.
Migraine sufferers who use cannabis for pain relief may be at higher odds of developing a “rebound” headache, according to new research from Stanford University.
The legalization bill would allow adults over 21 to possess up to 1 ounce (28 grams) of cannabis from January 1, 2024.
Hemp crops may have more in common with recreational, “drug-type” varieties of cannabis than previously thought, according to new research from the University of Minnesota.
Alisia Ratliff, CEO of Victus Capital Ventures, explores the world of cannabis separation techniques – the good, the bad, and the expensive.
The biotech and life sciences company Mydecine Innovations Group recently announced it had completed its first commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. Technology Networks caught up with the company's chief scientific officer, Rob Roscow, to find out more.
Around 77 percent of tested CBD topical products don't contain the correct amount of CBD advertised on the product’s label, according to a new investigation from Leafreport.